Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go.
作者信息
Fountzilas Christos, Hochwald Steven N
机构信息
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
出版信息
J Thorac Dis. 2019 Feb;11(2):351-353. doi: 10.21037/jtd.2018.11.111.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors in esophagogastric cancer: still a long way to go.免疫检查点抑制剂在食管癌和胃癌中的应用：仍有很长的路要走。
J Thorac Dis. 2019 Feb;11(2):351-353. doi: 10.21037/jtd.2018.11.111.
2
Pancreatic cancer and immune checkpoint inhibitors-still a long way to go.胰腺癌与免疫检查点抑制剂——仍有很长的路要走。
Transl Gastroenterol Hepatol. 2021 Jan 5;6:6. doi: 10.21037/tgh.2020.04.03. eCollection 2021.
3
Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.食管癌和胃癌的全身治疗：免疫检查点抑制
Chin Clin Oncol. 2017 Oct;6(5):53. doi: 10.21037/cco.2017.09.03.
4
Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.免疫疗法治疗内分泌恶性肿瘤：免疫检查点抑制剂引领潮流。
Endocr Relat Cancer. 2017 Dec;24(12):T261-T281. doi: 10.1530/ERC-17-0222. Epub 2017 Sep 11.
5
The Current Status of Immunotherapies in Esophagogastric Cancer.食管癌和胃癌免疫疗法的现状
Surg Oncol Clin N Am. 2017 Apr;26(2):277-292. doi: 10.1016/j.soc.2016.10.012.
6
Advances in the treatment of gastric cancer.胃癌治疗的进展
Curr Opin Gastroenterol. 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395.
7
The Current Status of Immunotherapies in Esophagogastric Cancer.免疫治疗在食管胃结合部癌中的现状。
Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338. doi: 10.1016/j.hoc.2018.12.007.
8
The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application.基于癌症免疫检查点疗法的突破：免疫检查点研究进展及其应用综述
Comb Chem High Throughput Screen. 2017;20(5):430-439. doi: 10.2174/1386207320666170315121728.
9
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
10
Checkpoint inhibitors in ovarian cancer: A review of preclinical data.卵巢癌中的检查点抑制剂：临床前数据综述
Gynecol Oncol Rep. 2019 Jun 18;29:48-54. doi: 10.1016/j.gore.2019.06.003. eCollection 2019 Aug.
本文引用的文献
1
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.免疫肿瘤学中联合治疗的快速实时评估（FRACTION）计划：免疫疗法的创新性、高通量临床筛选。
Eur J Cancer. 2018 Nov;103:259-266. doi: 10.1016/j.ejca.2018.07.127. Epub 2018 Oct 3.
2
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.CheckMate-032 研究：纳武利尤单抗和纳武利尤单抗联合伊匹单抗治疗转移性胃食管交界部癌患者的疗效和安全性。
J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15.
3
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.avelumab 对比医师选择的化疗作为晚期胃癌或胃食管结合部癌三线治疗的 III 期随机试验：JAVELIN Gastric 300 的主要分析结果
Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
4
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
5
Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer.转移性胃癌铂类化疗前后程序性死亡配体 1 表达模式的不一致性和变化。
Gastric Cancer. 2019 Jan;22(1):147-154. doi: 10.1007/s10120-018-0842-x. Epub 2018 Jun 2.
6
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
7
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.胃食管交界部癌系统治疗反应的遗传学预测因子。
Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.
8
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.抗程序性死亡受体-1 抗体派姆单抗治疗晚期食管癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2018 Jan 1;36(1):61-67. doi: 10.1200/JCO.2017.74.9846. Epub 2017 Nov 8.
9
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
10
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.肿瘤突变负荷作为预测多种癌症免疫治疗反应的独立标志物。
Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.
Zotero 插件